MK-8294-001

STX-478-101

BMS CA244-0001

MK-3120-002-00

DS2243-054

REGN7075

F60089IV101

IMA402-101

PANTUMOR 1479-0009

222730

ANV600-001

IMC-R117C-1004

SGNCEA5C-001

STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

STX-721-101

D6900C00001

M22TGA

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

GO43860

XL092-001

PROACTIVE

CyPep-1

VHIO17002

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors



<ul id="block-b900ec12-c696-4fd2-87a6-a9e347afef8d" class="wp-block-list">
<li>Code NKI: M24MKM</li>



<li>Code firma: MK-3120-002-00</li>



<li>Code clinicaltrials.gov: NCT06818643</li>
</ul>



Principal Investigator



Dr. Schutte



Drugs



MK-3120 (Nectin-4 ADC met als payload een topo I inhibitor)



<h2 class="wp-block-heading" id="block-c9bb39fc-6264-4a7d-a14b-2dd4aa21bac2">Summary</h2>



Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.



Read more on <a href="https://clinicaltrials.gov/study/NCT06818643">clinicaltrials.gov</a>.



<h2 class="wp-block-heading">Additional comments</h2>



<ul class="wp-block-list">
<li>Cohort A &#8211; Urothelial &#8211; open</li>



<li>Cohort B &#8211; HNSCC &#8211; open</li>



<li>Cohort C &#8211; Cervical &#8211; closed</li>



<li>Cohort D &#8211; Endometrial &#8211; open</li>



<li>Cohort E &#8211; TNBC &#8211; open</li>
</ul>